Information  X 
Enter a valid email address

UNIQURE ORD (0EE0)

Date Time Source Announcement
15 Apr 2019 5:15 pm
GNW
uniQure Announces Presentations at the Upcoming Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT)
08 Apr 2019 12:00 pm
GNW
uniQure Receives FDA Fast Track Designation for AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
29 Mar 2019 11:00 am
GNW
uniQure to Participate in Multiple Upcoming Industry Conferences
01 Mar 2019 12:00 pm
GNW
uniQure to Participate in Multiple Upcoming Industry Conferences
28 Feb 2019 12:00 pm
GNW
uniQure Announces 2018 Financial Results and Highlights Recent Company Progress
27 Feb 2019 12:00 pm
GNW
uniQure Presents New Preclinical Data on AMT-130 at the CHDI’s 14th Annual Huntington’s Disease Therapeutics Conference
15 Feb 2019 12:24 pm
GNW
uniQure Announces Publications on AAV Gene Therapy Approach to Treating Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD) in the Journal Molecular Therapy Nucleic Acids
08 Feb 2019 12:00 pm
GNW
uniQure Announces Updated Clinical Data from Phase IIb Study of AMT-061 in Patients with Hemophilia B
04 Feb 2019 12:00 pm
GNW
uniQure Announces First Patient Treated in HOPE-B Pivotal Trial of AMT-061 in Patients with Hemophilia B
30 Jan 2019 12:00 pm
GNW
uniQure to Participate in Multiple Upcoming Industry Conferences
22 Jan 2019 12:00 pm
GNW
uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-130 in Huntington’s Disease
03 Dec 2018 12:00 pm
GNW
uniQure Announces Long-Term Clinical Data from Ongoing Phase I/II Trial of AMT-060 and Confirms Dose for AMT-061 Pivotal Study in Hemophilia B
19 Nov 2018 5:15 pm
GNW
uniQure Highlights Pipeline Expansion and Advancements in Technology at Research & Development Day
15 Nov 2018 12:00 pm
GNW
uniQure Announces Initial Topline Data from Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B
06 Nov 2018 12:00 pm
GNW
uniQure Announces Third Quarter 2018 Financial Results and Highlights Company Progress
05 Nov 2018 12:00 pm
GNW
uniQure to Host Research & Development Day on Monday, November 19 in New York City
31 Oct 2018 11:00 am
GNW
uniQure to Participate in Multiple Upcoming Industry Conferences
18 Oct 2018 11:55 am
GNW
uniQure Announces Development of a Highly Potent, Next-Generation Promoter for Liver-Directed Gene Therapies
17 Oct 2018 12:00 pm
GNW
uniQure Presents New Data Demonstrating Its Large-Scale Manufacturing Capabilities at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting
16 Oct 2018 12:00 pm
GNW
uniQure Announces Presentations at the Upcoming Annual Meeting of The European Society of Gene and Cell Therapy (ESGCT)
28 Sep 2018 12:00 pm
GNW
uniQure to Participate in Multiple Upcoming Industry Conferences
24 Sep 2018 12:00 pm
GNW
uniQure Provides Update on Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B
30 Aug 2018 12:00 pm
GNW
uniQure to Participate at Multiple Upcoming Conferences
23 Aug 2018 12:00 pm
GNW
uniQure Announces First Patient Treated in Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B
08 Aug 2018 12:00 pm
GNW
uniQure Announces Second Quarter 2018 Financial Results and Highlights Company Progress
28 Jun 2018 12:00 pm
GNW
uniQure Enrolls First Patient in Phase III HOPE-B Pivotal Study of AMT-061 in Patients with Hemophilia B
13 Jun 2018 12:00 pm
GNW
uniQure Announces New Appointments to its Board of Directors
29 May 2018 12:00 pm
GNW
uniQure Announces the Issuance of New Patents Providing Broad Protection of the Padua Variant of Factor IX in Gene Therapy
21 May 2018 12:00 pm
GNW
uniQure Presents New Data Demonstrating Clinical Benefit in Hemophilia B Patients with Pre-Existing Anti-AAV5 Neutralizing Antibodies
18 May 2018 12:00 pm
GNW
uniQure Presents Preclinical Data Demonstrating Advances in the Distribution of Gene Therapy
07 May 2018 4:53 pm
GNW
uniQure Announces Closing Of Public Offering And Full Exercise Of The Underwriters' Option To Purchase Additional Shares
03 May 2018 12:38 am
GNW
uniQure Announces Pricing of its Public Offering
01 May 2018 9:10 pm
GNW
uniQure Announces Proposed Public Offering
30 Apr 2018 5:00 pm
GNW
uniQure Announces Presentations at the Upcoming Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT)
  12:05 pm
GNW
uniQure Announces First Quarter 2018 Financial Results and Highlights Company Progress
14 Mar 2018 11:00 am
GNW
uniQure Announces 2017 Financial Results and Recent Company Progress
27 Feb 2018 12:00 pm
GNW
uniQure to Participate in Multiple Conferences in March
01 Feb 2018 12:00 pm
GNW
uniQure to Participate in Multiple Conferences in February
22 Jan 2018 12:00 pm
GNW
uniQure Receives Orphan Medicinal Product Designation in Europe for AMT-130 in Huntington's disease
08 Jan 2018 12:00 pm
GNW
uniQure Provides Year-End 2017 Corporate Update and Outlines Near-Term Objectives to Further Drive Shareholder Value
18 Dec 2017 12:00 pm
GNW
uniQure Announces Publication in the Journal Blood of Clinical Data from Phase I/II Trial of AMT-060 In Patients with Severe Hemophilia B
11 Dec 2017 9:01 pm
GNW
uniQure Added to NASDAQ Biotechnology Index
  12:00 pm
GNW
uniQure Announces Updated, Long-Term Clinical Data from Ongoing Phase I/II Trial of AMT-060 In Patients with Severe Hemophilia B
09 Dec 2017 2:00 pm
GNW
uniQure Announces Presentation of Non-Clinical Data of AMT-061 at the 59th American Society of Hematology (ASH) Annual Meeting
01 Nov 2017 1:10 pm
GNW
uniQure Announces Presentations at the 59th American Society of Hematology (ASH) Annual Meeting
  11:00 am
GNW
uniQure Announces Third Quarter 2017 Financial Results and Recent Company Progress
31 Oct 2017 8:09 pm
GNW
uniQure Announces Multiple Company Presentations at Upcoming November Conferences
27 Oct 2017 9:03 pm
GNW
uniQure Announces Closing of its Public Offering
25 Oct 2017 1:14 am
GNW
uniQure Announces Pricing of its Public Offering
23 Oct 2017 9:09 pm
GNW
uniQure Announces Proposed Public Offering
19 Oct 2017 12:05 pm
GNW
uniQure Strengthens Intellectual Property Portfolio with Acquisition of Patent Family Providing Broad Protection of the Hyperactive Padua Variant of Factor IX (FIX-Padua)
  12:00 pm
GNW
uniQure Announces Hemophilia B Gene Therapy Program To Enter Pivotal Study With FIX-Padua Variant in 2018
18 Oct 2017 12:00 pm
GNW
uniQure Presents New Preclinical Data on AMT-130 in Huntington's Disease at the ESGCT 25th Anniversary Congress in Berlin
06 Oct 2017 12:00 pm
GNW
uniQure Announces FDA Orphan Drug Designation for AMT-130 in Huntington's disease
02 Oct 2017 12:00 pm
GNW
uniQure Announces Company Presentations at Upcoming October Conferences
24 Aug 2017 12:00 pm
GNW
uniQure Announces Company Participation at Citi Healthcare Conference
08 Aug 2017 12:00 pm
GNW
uniQure Announces Second Quarter 2017 Financial Results and Recent Company Progress
07 Aug 2017 12:00 pm
GNW
uniQure Announces Leadership Team Appointments and Nominations to its Board of Directors
31 Jul 2017 12:00 pm
GNW
uniQure Reacquires Development and Commercialization Rights for its Gene Therapy Candidate in Hemophilia B
21 Jul 2017 12:00 pm
GNW
uniQure Announces the Successful Development and Scale-up of Manufacturing Processes for Its Hemophilia B Gene Therapy Program
 
Headlines
Top categories
Company finder
Forthcoming announcements

a d v e r t i s e m e n t